Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
Tomaszewska, A., Jagasia, M., Beohou, E., van der Werf, S., Blaise, D., Kanfer, E. ... Basak, G. W. (2021). Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. Frontiers in Immunology, 11.. doi: 10.3389/fimmu.2020.613954
Tomaszewska, Agnieszka, et al. "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies." Frontiers in Immunology, vol. 11, 2021. https://doi.org/10.3389/fimmu.2020.613954
Tomaszewska, Agnieszka, Madan Jagasia, Eric Beohou, Steffie van der Werf, Didier Blaise, Edward Kanfer, Noel Milpied, et al. "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies." Frontiers in Immunology 11 (2021). https://doi.org/10.3389/fimmu.2020.613954
Tomaszewska, A., et al. (2021) 'Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies', Frontiers in Immunology, 11. doi: 10.3389/fimmu.2020.613954
Tomaszewska A, Jagasia M, Beohou E, van der Werf S, Blaise D, Kanfer E, and sur.. Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. Frontiers in Immunology [Internet]. 2021 February [cited 2024 August 17];11. doi: 10.3389/fimmu.2020.613954
A. Tomaszewska, et al., "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies", Frontiers in Immunology, vol. 11, February 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:878916. [Accessed: 17 August 2024]